Back to Journals » Biologics: Targets and Therapy » Volume 4

Review

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

       
Total article views   HTML views PDF downloads Totals
12,640 Dovepress* 12,640+ 2,688 15,328
Totals 12,640 2,688 15,328
*Since 30 April 2010
+Since July 2016

View citations on Google Scholar